Published in Circ Res on July 07, 2011
ACT34-CMI -- Adult Autologous CD34+ Stem Cells | NCT00300053
Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes. Circ Res (2014) 2.46
Exosomes from human CD34(+) stem cells mediate their proangiogenic paracrine activity. Circ Res (2011) 2.31
Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA (2014) 2.19
Interleukin-10 deficiency impairs bone marrow-derived endothelial progenitor cell survival and function in ischemic myocardium. Circ Res (2011) 1.99
Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models. Am J Respir Crit Care Med (2013) 1.71
Sonic hedgehog-modified human CD34+ cells preserve cardiac function after acute myocardial infarction. Circ Res (2012) 1.70
Activation of Toll-like receptor 3 amplifies mesenchymal stem cell trophic factors and enhances therapeutic potency. Am J Physiol Cell Physiol (2012) 1.67
Use of mesenchymal stem cells for therapy of cardiac disease. Circ Res (2015) 1.57
Enhanced Cardiac Regenerative Ability of Stem Cells After Ischemia-Reperfusion Injury: Role of Human CD34(+) Cells Deficient in MicroRNA-377. J Am Coll Cardiol (2015) 1.45
Coronary microvascular dysfunction: an update. Eur Heart J (2013) 1.28
CD34-positive stem cells: in the treatment of heart and vascular disease in human beings. Tex Heart Inst J (2011) 1.21
Manipulation of a VEGF-Notch signaling circuit drives formation of functional vascular endothelial progenitors from human pluripotent stem cells. Cell Res (2014) 1.14
Biological pacemaker created by minimally invasive somatic reprogramming in pigs with complete heart block. Sci Transl Med (2014) 1.12
Circulating CD34(+) progenitor cell frequency is associated with clinical and genetic factors. Blood (2013) 1.07
Endothelial progenitor cells and integrins: adhesive needs. Fibrogenesis Tissue Repair (2012) 1.07
Cotransplantation with specific populations of spina bifida bone marrow stem/progenitor cells enhances urinary bladder regeneration. Proc Natl Acad Sci U S A (2013) 1.03
Up-regulation of miR-210 by vascular endothelial growth factor in ex vivo expanded CD34+ cells enhances cell-mediated angiogenesis. J Cell Mol Med (2012) 1.01
The membrane scaffold CD82 regulates cell adhesion by altering α4 integrin stability and molecular density. Mol Biol Cell (2014) 1.00
Regenerative heart failure therapy headed for optimization. Eur Heart J (2014) 0.98
Endothelial progenitor cells in cardiovascular diseases. World J Stem Cells (2014) 0.98
Intramyocardial injection of autologous bone marrow-derived ex vivo expanded mesenchymal stem cells in acute myocardial infarction patients is feasible and safe up to 5 years of follow-up. J Cardiovasc Transl Res (2013) 0.97
Comparison of human adipose-derived stem cells isolated from subcutaneous, omental, and intrathoracic adipose tissue depots for regenerative applications. Stem Cells Transl Med (2013) 0.96
Vasculogenic conditioning of peripheral blood mononuclear cells promotes endothelial progenitor cell expansion and phenotype transition of anti-inflammatory macrophage and T lymphocyte to cells with regenerative potential. J Am Heart Assoc (2014) 0.93
Endothelial progenitor cells in cardiovascular disease and chronic inflammation: from biomarker to therapeutic agent. Biomark Med (2011) 0.92
Tracking of stem cells in vivo for cardiovascular applications. J Cardiovasc Magn Reson (2014) 0.92
Key developments in stem cell therapy in cardiology. Regen Med (2012) 0.92
Adult Stem Cell Therapy and Heart Failure, 2000 to 2016: A Systematic Review. JAMA Cardiol (2016) 0.90
Rosuvastatin enhances angiogenesis via eNOS-dependent mobilization of endothelial progenitor cells. PLoS One (2013) 0.90
Progenitor cell mobilization and recruitment: SDF-1, CXCR4, α4-integrin, and c-kit. Prog Mol Biol Transl Sci (2012) 0.87
A characterization and targeting of the infarct border zone in a swine model of myocardial infarction. Clin Transl Sci (2012) 0.87
Safety and feasibility of percutaneous retrograde coronary sinus delivery of autologous bone marrow mononuclear cell transplantation in patients with chronic refractory angina. J Transl Med (2011) 0.87
Concise Review: Review and Perspective of Cell Dosage and Routes of Administration From Preclinical and Clinical Studies of Stem Cell Therapy for Heart Disease. Stem Cells Transl Med (2015) 0.87
Bone Marrow Stem Cell Treatment for Ischemic Heart Disease in Patients with No Option of Revascularization: A Systematic Review and Meta-Analysis. PLoS One (2013) 0.87
Concise review: therapeutic potential of adipose tissue-derived angiogenic cells. Stem Cells Transl Med (2012) 0.87
Potential Strategies to Address the Major Clinical Barriers Facing Stem Cell Regenerative Therapy for Cardiovascular Disease: A Review. JAMA Cardiol (2016) 0.86
The Clinical Status of Stem Cell Therapy for Ischemic Cardiomyopathy. Stem Cells Int (2015) 0.86
Impact of Cell Therapy on Myocardial Perfusion and Cardiovascular Outcomes in Patients With Angina Refractory to Medical Therapy: A Systematic Review and Meta-Analysis. Circ Res (2016) 0.85
Therapeutic revascularisation of ischaemic tissue: the opportunities and challenges for therapy using vascular stem/progenitor cells. Stem Cell Res Ther (2012) 0.85
Stem cell-derived endothelial cells for cardiovascular disease: a therapeutic perspective. Br J Clin Pharmacol (2013) 0.84
Negative Regulation of miR-375 by Interleukin-10 Enhances Bone Marrow-Derived Progenitor Cell-Mediated Myocardial Repair and Function After Myocardial Infarction. Stem Cells (2015) 0.84
Predictors of long-term clinical endpoints in patients with refractory angina. J Am Heart Assoc (2015) 0.84
Revisiting cardiovascular regeneration with bone marrow-derived angiogenic and vasculogenic cells. Br J Pharmacol (2013) 0.84
Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial. Cell Transplant (2015) 0.83
Angiogenic Mechanisms of Human CD34(+) Stem Cell Exosomes in the Repair of Ischemic Hindlimb. Circ Res (2017) 0.82
Optimized processing of growth factor mobilized peripheral blood CD34+ products by counterflow centrifugal elutriation. Stem Cells Transl Med (2012) 0.82
The effects of mechanical stress on the growth, differentiation, and paracrine factor production of cardiac stem cells. PLoS One (2011) 0.82
Endothelial progenitor cells in cardiovascular diseases: from biomarker to therapeutic agent. Regen Med Res (2013) 0.82
Enhancing the function of CD34(+) cells by targeting plasminogen activator inhibitor-1. PLoS One (2013) 0.81
Stem cell-based therapies to promote angiogenesis in ischemic cardiovascular disease. Am J Physiol Heart Circ Physiol (2015) 0.81
Bilateral administration of autologous CD133+ cells in ambulatory patients with refractory critical limb ischemia: lessons learned from a pilot randomized, double-blind, placebo-controlled trial. Cytotherapy (2014) 0.81
Concise Review: Endothelial Progenitor Cells in Regenerative Medicine: Applications and Challenges. Stem Cells Transl Med (2016) 0.80
Regenerative medicine and the gut. Gastroenterology (2011) 0.80
Extracellular vesicles in cardiovascular disease: are they Jedi or Sith? J Physiol (2016) 0.80
Catheter-based intramyocardial delivery (NavX) of adenovirus achieves safe and accurate gene transfer in pigs. PLoS One (2013) 0.80
Genistein promotes endothelial colony-forming cell (ECFC) bioactivities and cardiac regeneration in myocardial infarction. PLoS One (2014) 0.80
Myocardial repair and regeneration: bone marrow or cardiac stem cells? Mol Ther (2012) 0.80
Laser-supported CD133+ cell therapy in patients with ischemic cardiomyopathy: initial results from a prospective phase I multicenter trial. PLoS One (2014) 0.80
Adipose-derived stem cells: selecting for translational success. Regen Med (2015) 0.79
Blood vessel repair and regeneration in the ischaemic heart. Open Heart (2014) 0.79
Can endothelial progenitor cells treat patients with refractory angina? Circ Res (2014) 0.79
Significant improvement of direct reprogramming efficacy of fibroblasts into progenitor endothelial cells by ETV2 and hypoxia. Stem Cell Res Ther (2016) 0.79
Lysophosphatidic acid enhances survival of human CD34(+) cells in ischemic conditions. Sci Rep (2015) 0.78
Early outgrowth pro-angiogenic cell number and function do not correlate with left ventricular structure and function in conventional hemodialysis patients: a cross-sectional study. Can J Kidney Health Dis (2015) 0.78
Cardiac tissue engineering and regeneration using cell-based therapy. Stem Cells Cloning (2015) 0.78
Guanylate-binding protein 1 expression from embryonal endothelial progenitor cells reduces blood vessel density and cellular apoptosis in an axially vascularised tissue-engineered construct. BMC Biotechnol (2012) 0.78
Advances in the Treatment of Ischemic Diseases by Mesenchymal Stem Cells. Stem Cells Int (2016) 0.78
Stem cell therapy in patients with heart failure. Methodist Debakey Cardiovasc J (2013) 0.78
Stem cell therapy for heart disease. J Gen Intern Med (2013) 0.78
Chronic endurance exercise affects paracrine action of CD31+ and CD34+ cells on endothelial tube formation. Am J Physiol Heart Circ Physiol (2015) 0.78
Stable angina pectoris: antianginal therapies and future directions. Nat Rev Cardiol (2011) 0.77
Cardiovascular repair with bone marrow-derived cells. Blood Res (2013) 0.77
Exosome and its roles in cardiovascular diseases. Heart Fail Rev (2015) 0.77
Translational aspects of cardiac cell therapy. J Cell Mol Med (2015) 0.77
Regenerative principles enrich cardiac rehabilitation practice. Am J Phys Med Rehabil (2014) 0.77
Migration towards SDF-1 selects angiogenin-expressing bone marrow monocytes endowed with cardiac reparative activity in patients with previous myocardial infarction. Stem Cell Res Ther (2015) 0.77
CD34+ autologous human stem cells in treating refractory angina. Circ Res (2011) 0.77
Alcohol consumption negates estrogen-mediated myocardial repair in ovariectomized mice by inhibiting endothelial progenitor cell mobilization and function. J Biol Chem (2013) 0.77
Full GMP-Compliant Validation of Bone Marrow-Derived Human CD133 (+) Cells as Advanced Therapy Medicinal Product for Refractory Ischemic Cardiomyopathy. Biomed Res Int (2015) 0.77
Clinical trials of cardiac repair with adult bone marrow- derived cells. Methods Mol Biol (2013) 0.77
Effect of intramyocardial bone marrow-derived mononuclear cell injection on cardiac sympathetic innervation in patients with chronic myocardial ischemia. Int J Cardiovasc Imaging (2014) 0.76
Critical Roles of Reactive Oxygen Species in Age-Related Impairment in Ischemia-Induced Neovascularization by Regulating Stem and Progenitor Cell Function. Oxid Med Cell Longev (2015) 0.76
Stem Cell-Based Therapies in Chagasic Cardiomyopathy. Biomed Res Int (2015) 0.76
Apoptosis-Resistant Cardiac Progenitor Cells Modified With Apurinic/Apyrimidinic Endonuclease/Redox Factor 1 Gene Overexpression Regulate Cardiac Repair After Myocardial Infarction. Stem Cells Transl Med (2016) 0.76
Enhancing endothelial progenitor cell for clinical use. World J Stem Cells (2015) 0.76
Created equal? The many facets of cell reprogramming. Circ Res (2012) 0.76
Enhanced infarct myocardium repair mediated by thermosensitive copolymer hydrogel-based stem cell transplantation. Exp Biol Med (Maywood) (2014) 0.76
Ultrasound-mediated microbubble destruction enhances the therapeutic effect of intracoronary transplantation of bone marrow stem cells on myocardial infarction. Int J Clin Exp Pathol (2015) 0.75
Enhanced potency of cell-based therapy for ischemic tissue repair using an injectable bioactive epitope presenting nanofiber support matrix. J Mol Cell Cardiol (2014) 0.75
Association between High Endocardial Unipolar Voltage and Improved Left Ventricular Function in Patients with Ischemic Cardiomyopathy. Tex Heart Inst J (2016) 0.75
Cell Therapy Augments Myocardial Perfusion and Improves Quality of Life in Patients With Refractory Angina. Circ Res (2016) 0.75
Priming mononuclear cells to improve outcomes of regenerative therapy. J Am Heart Assoc (2014) 0.75
Safety and feasibility of mapping and stem cell delivery in the presence of an implanted left ventricular assist device: a preclinical investigation in sheep. Tex Heart Inst J (2013) 0.75
What Is the Future of Cell-Based Therapy for Acute Myocardial Infarction. Circ Res (2017) 0.75
Experimental and early investigational drugs for angina pectoris. Expert Opin Investig Drugs (2016) 0.75
Lack of cardiac nerve sprouting after intramyocardial transplantation of bone marrow-derived stem cells in a swine model of chronic ischemic myocardium. J Cardiovasc Transl Res (2012) 0.75
Restoration of Hydrogen Sulfide Production in Diabetic Mice Improves Reparative Function of Bone Marrow Cells. Circulation (2016) 0.75
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med (2004) 49.02
Isolation of putative progenitor endothelial cells for angiogenesis. Science (1997) 30.27
Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation (2009) 27.89
Universal definition of myocardial infarction. Circulation (2007) 11.69
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol (2003) 8.95
Universal definition of myocardial infarction. J Am Coll Cardiol (2007) 8.68
Angiogenesis. Annu Rev Med (2006) 6.94
Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial. Lancet (2002) 3.31
Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood (2008) 3.11
Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation (2007) 2.88
The problem of chronic refractory angina; report from the ESC Joint Study Group on the Treatment of Refractory Angina. Eur Heart J (2002) 2.68
CD34-positive cells exhibit increased potency and safety for therapeutic neovascularization after myocardial infarction compared with total mononuclear cells. Circulation (2006) 2.51
Women and ischemic heart disease: evolving knowledge. J Am Coll Cardiol (2009) 2.49
Dose-dependent contribution of CD34-positive cell transplantation to concurrent vasculogenesis and cardiomyogenesis for functional regenerative recovery after myocardial infarction. Circulation (2006) 2.17
Prognostic significance of small troponin I rise after a successful elective percutaneous coronary intervention of a native artery. Am J Cardiol (2009) 2.14
Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial). Eur Heart J (2007) 2.11
Prognostic value of troponin after elective percutaneous coronary intervention: A meta-analysis. Catheter Cardiovasc Interv (2008) 1.99
Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial. JAMA (2009) 1.99
Human studies of angiogenic gene therapy. Circ Res (2009) 1.92
Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial. J Am Coll Cardiol (2005) 1.92
Direct myocardial revascularization and angiogenesis--how many patients might be eligible? Am J Cardiol (1999) 1.32
Preliminary animal and clinical experiences using an electromechanical endocardial mapping procedure to distinguish infarcted from healthy myocardium. Circulation (1998) 1.26
Mesenchymal cell transplantation and myocardial remodeling after myocardial infarction. Circulation (2009) 1.23
Myocardial infarction after percutaneous coronary intervention: a meta-analysis of troponin elevation applying the new universal definition. QJM (2009) 1.17
Comparison between left ventricular electromechanical mapping and radionuclide perfusion imaging for detection of myocardial viability. Circulation (1998) 1.13
Multiparametric flow cytometric analysis of biochemical and functional events associated with apoptosis and oncosis using the 7-aminoactinomycin D assay. J Immunol Methods (2002) 1.06
Clinical and research issues regarding chronic advanced coronary artery disease part II: Trial design, outcomes, and regulatory issues. Am Heart J (2008) 1.00
Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: double-edged swords. J Am Coll Cardiol (2005) 0.94
Clinical and research issues regarding chronic advanced coronary artery disease: part I: Contemporary and emerging therapies. Am Heart J (2008) 0.92
Pharmacological treatment and perceived health status during 1-year follow up in patients diagnosed with coronary artery disease, but ineligible for revascularization. Results from the Euro Heart Survey on Coronary Revascularization. Eur J Cardiovasc Nurs (2006) 0.89
Images in cardiovascular medicine. Left ventricular electromechanical mapping of myocardial ischemia. Circulation (1999) 0.87
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
Ethical and scientific implications of the globalization of clinical research. N Engl J Med (2009) 11.42
Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA (2002) 8.28
A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol (2009) 8.13
Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA (2006) 7.81
Circadian dependence of infarct size and left ventricular function after ST elevation myocardial infarction. Circ Res (2011) 5.87
Association between hospital process performance and outcomes among patients with acute coronary syndromes. JAMA (2006) 5.78
Obesity paradox in patients with hypertension and coronary artery disease. Am J Med (2007) 5.61
Efficacy of a device to narrow the coronary sinus in refractory angina. N Engl J Med (2015) 5.36
Endoscopic versus open vein-graft harvesting in coronary-artery bypass surgery. N Engl J Med (2009) 5.19
Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med (2006) 5.18
Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA (2004) 5.11
Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med (2006) 5.07
Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA (2010) 5.06
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet (2002) 5.04
Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med (2011) 4.81
Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol (2012) 4.29
Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med (2013) 4.16
Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA (2011) 4.09
Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA (2003) 3.93
Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med (2006) 3.90
Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J (2008) 3.84
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet (2013) 3.74
Conversion of cardiovascular conference abstracts to publications. Circulation (2012) 3.71
Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA (2007) 3.48
Perceived knowledge among patients cared for by nephrologists about chronic kidney disease and end-stage renal disease therapies. Kidney Int (2008) 3.36
Intravenous platelet blockade with cangrelor during PCI. N Engl J Med (2009) 3.31
A regional system to provide timely access to percutaneous coronary intervention for ST-elevation myocardial infarction. Circulation (2007) 3.26
Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol (2006) 3.25
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med (2011) 3.20
Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet (2013) 3.17
Relationship of physical fitness vs body mass index with coronary artery disease and cardiovascular events in women. JAMA (2004) 3.17
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet (2010) 2.98
Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med (2014) 2.90
"False-positive" cardiac catheterization laboratory activation among patients with suspected ST-segment elevation myocardial infarction. JAMA (2007) 2.89
Patients with coronary artery disease not amenable to traditional revascularization: prevalence and 3-year mortality. Catheter Cardiovasc Interv (2010) 2.88
Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. Circulation (2007) 2.88
Transient midventricular ballooning syndrome: a new variant. J Am Coll Cardiol (2006) 2.85
Myocardial injury and long-term mortality following moderate to severe carbon monoxide poisoning. JAMA (2006) 2.83
ST-elevation myocardial infarction diagnosed after hospital admission. Circulation (2014) 2.83
Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation (2008) 2.82
Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol (2007) 2.73
Symptom presentation of women with acute coronary syndromes: myth vs reality. Arch Intern Med (2007) 2.70
ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol (2008) 2.67
Persistent chest pain predicts cardiovascular events in women without obstructive coronary artery disease: results from the NIH-NHLBI-sponsored Women's Ischaemia Syndrome Evaluation (WISE) study. Eur Heart J (2006) 2.67
Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J (2008) 2.64
Intracoronary optical coherence tomography: a comprehensive review clinical and research applications. JACC Cardiovasc Interv (2009) 2.64
A simple method for noninvasive estimation of pulmonary vascular resistance. J Am Coll Cardiol (2003) 2.62
Insights from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: Part I: gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol (2006) 2.57
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet (2012) 2.53
Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation (2004) 2.50
Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med (2009) 2.49
Adverse cardiovascular outcomes in women with nonobstructive coronary artery disease: a report from the Women's Ischemia Syndrome Evaluation Study and the St James Women Take Heart Project. Arch Intern Med (2009) 2.48
Revisiting the culprit lesion in non-Q-wave myocardial infarction. Results from the VANQWISH trial angiographic core laboratory. J Am Coll Cardiol (2002) 2.41
Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension (2007) 2.37
Mental stress-induced ischemia and all-cause mortality in patients with coronary artery disease: Results from the Psychophysiological Investigations of Myocardial Ischemia study. Circulation (2002) 2.32
Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol (2004) 2.31
Abnormal coronary vasomotion as a prognostic indicator of cardiovascular events in women: results from the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation (2004) 2.30
Predictors and outcomes of resistant hypertension among patients with coronary artery disease and hypertension. J Hypertens (2014) 2.28
Retracted Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab (2008) 2.21
Cardiovascular manifestations of moderate to severe carbon monoxide poisoning. J Am Coll Cardiol (2005) 2.19
Sex differences in mortality following acute coronary syndromes. JAMA (2009) 2.17
Harmful effects of NSAIDs among patients with hypertension and coronary artery disease. Am J Med (2011) 2.17
Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome. Am Heart J (2013) 2.14
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet (2009) 2.13
The failure of orally administered glycoprotein IIb/IIIa inhibitors to prevent recurrent cardiac events. Am J Med (2002) 2.09
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol (2007) 2.08
Timing of hormone therapy, type of menopause, and coronary disease in women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation. Menopause (2011) 2.06
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation (2013) 2.03
Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. Blood (2012) 2.03